Quantcast
Last updated on April 17, 2014 at 8:50 EDT

Latest Paladin Labs Inc. Stories

2014-04-10 08:29:34

GREENWOOD VILLAGE, Colo., April 10, 2014 /PRNewswire/ -- Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute...

2014-02-28 12:27:50

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- -- Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company -- Creates a compelling financial and operational platform for future growth -- Establishes Endo's global pharmaceuticals footprint -- Endo Health Solutions Inc. becomes Endo International plc Endo International plc (Nasdaq: ENDP; TSX: ENL), formerly Endo Health Solutions Inc., announced today that it has completed...

2014-02-26 12:26:21

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin") were approved by Endo's shareholders. As previously announced, on November 5, 2013, Endo and Paladin entered into an arrangement agreement pursuant to which each of Endo and Paladin will be acquired by a new Irish holding company, Endo...

2013-12-19 12:29:02

MALVERN, Pa. and MONTREAL, Dec. 19, 2013 /PRNewswire/ -- Endo Health Solutions (NASDAQ: ENDP) ("Endo") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act") in connection with Endo's proposed acquisition of Paladin Labs Inc. (TSX: PLB) ("Paladin Labs") was terminated by the United States Federal Trade Commission on December 17, 2013. Endo also today announced that the Canadian Competition Bureau issued a...

2013-11-05 08:33:20

MALVERN, Pa. and MONTREAL, Nov. 5, 2013 /PRNewswire/ -- -- Accelerates Endo's transformation to leading global specialty healthcare company and creates platform for future growth -- Paladin Labs' proven Canadian franchise, robust near-term pipeline and emerging market business complement Endo's U.S. strengths -- Combined company expects to grow presence in North America and internationally -- Stock and cash transaction values Paladin Labs at...

2013-07-10 20:22:10

MISSISSAUGA, ON and MONTREAL, July 10, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, and Paladin Labs Inc. (TSX: PLB), a leading specialty pharmaceutical company today announced that they have completed the amended loan arrangements (the "Loan") the details of which were previously announced on June...

2013-07-05 16:22:23

BELLEVILLE, ON, July 5, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC) ("Bioniche") and Paladin Labs Inc.(TSX:  PLB) ("Paladin") today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin(TM). This collaboration was originally announced on...

2013-06-17 16:25:54

MISSISSAUGA, ON and MONTREAL, QC, June 17, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, and Paladin Labs Inc. (TSX: PLB), a leading specialty pharmaceutical company today announced that they have amended their loan arrangements (the "Loan") originally agreed to in May 2012.  In May of 2012, Nuvo...

2013-06-05 20:23:44

BELLEVILLE, ON, June 5, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC) ("Bioniche") and Paladin Labs Inc.(TSX:  PLB) ("Paladin") today announced a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin(TM). Debt Refinancing and Equity Paladin today acquired Bioniche's existing debt facility with Capital Royalty...

2012-10-09 19:21:19

SYDNEY and BEDMINSTER, N.J., Oct. 9, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with Paladin Labs Inc. ("Paladin") (TSX:PLB) for the Canadian commercialisation rights to MOXDUO(®), a patented, immediate release formulation of morphine and oxycodone. Paladin is a leading Canadian specialty pharmaceutical company headquartered in Montreal, Canada, and is listed on the Toronto Stock Exchange. Paladin has working...